Tempus AI, Inc. TEM R3KAIPHARMA
Company Overview
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Why Investors Should Care
Revenue has grown at a 58.3% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $1.27B (+83.4% YoY); net profit $-245.03M.
- Trailing 12 Months Year-on-year growth — revenue +21.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 58.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 58.29% |
| 1 Year: | 21.60% |
Stock Price Performance
| 1 Year: | -7.20% |
| 6 Months: | +23.65% |
| 3 Months: | +39.18% |
| 1 Month: | +40.11% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
Multi-modal cancer/pharma data + AI applications for precision medicine.
- AI-driven precision medicine Tempus combines a vast library of clinical and molecular data with AI to support oncology diagnostics and treatment decisions.
- Generative & diagnostic AI AI models analyse genomic and clinical data to power diagnostics and decision support.
- Data licensing Its proprietary multimodal health dataset is licensed to pharma for AI-driven drug development.
- A leading 'AI in healthcare' data platform with a large proprietary clinical dataset.
- Strong ~36% revenue growth across diagnostics and data licensing.
- Loss-making (net margin ~-22%) — scaling toward profitability.
- Reimbursement, data-privacy and execution are key risks.
Curated from public filings and analyst commentary; figures are illustrative.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 58.3% over 5 years.
CONS
- Trading 37.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TEM Tempus AI, Inc. R3KAIPHARMA | 64.62 | -44.88 | $11.33B | 0.00% | -13.29% | -67.44% | 58.29% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 132.42M | 136.06M | 145.82M | 165.97M | 180.93M | 255.74M | 314.63M | 334.21M | 348.12M | 382.49M |
| Operating Income | -45.14M | -44.79M | -53.27M | -533.49M | -53.62M | -68.69M | -61.77M | -61.00M | -84.71M | -75.91M |
| Net Income | -55.83M | -53.43M | -64.74M | -552.21M | -75.84M | -68.04M | -42.84M | -79.98M | -125.92M | 5.64M |
| Diluted EPS | -1.07 | -1.03 | -1.47 | -6.86 | -0.46 | -0.40 | -0.25 | -0.46 | -0.71 | 0.03 |
| R&D Expense | 22.17M | 23.23M | 24.34M | 68.03M | 27.35M | 35.87M | 41.62M | 44.96M | 48.24M | 52.64M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 320.67M | 531.82M | 693.40M | 1.27B |
| Operating Income | -265.44M | -196.08M | -691.08M | -252.87M |
| Net Income | -289.81M | -214.12M | -705.81M | -245.03M |
| Diluted EPS | -5.30 | -4.20 | -6.23 | -1.41 |
| R&D Expense | 83.16M | 90.34M | 149.32M | 172.92M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | - | 564.05M | 926.12M | 2.27B |
| Total Equity | -807.49M | -1.13B | -1.38B | 56.34M | 491.33M |
| Cash & Equivalents | - | 302.94M | 165.77M | 340.95M | 604.79M |
| Total Liabilities | - | - | 840.67M | 869.78M | 1.78B |
| Current Liabilities | - | - | 232.63M | 291.07M | 372.39M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -168.20M | -214.34M | -189.04M | -218.09M |
| Investing Cash Flow | -57.94M | -40.31M | -130.39M | -398.36M |
| Financing Cash Flow | 251.39M | 117.55M | 494.33M | 884.12M |
| Capital Expenditure | -18.38M | -34.61M | -22.12M | -21.05M |
| Free Cash Flow | -186.58M | -248.95M | -211.17M | -239.14M |
| Dividends Paid | 5.62M | 5.62M | 5.62M | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | -82.8% | -36.9% | -99.7% | -19.9% |
| Net Margin % | -90.4% | -40.3% | -101.8% | -19.3% |
| ROE % | 25.7% | 15.5% | -1,252.8% | -49.9% |
| ROCE % | - | -59.2% | -108.8% | -13.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | ARK Investment Management, LLC | 5.71% | 10.02M | $641.85M |
| 2 | Blackrock Inc. | 4.73% | 8.29M | $530.96M |
| 3 | BAILLIE GIFFORD & CO | 4.67% | 8.19M | $524.50M |
| 4 | Softbank Group Corporation | 3.08% | 5.41M | $346.16M |
| 5 | JPMORGAN CHASE & CO | 2.84% | 4.99M | $319.50M |
| 6 | Vanguard Capital Management LLC | 2.84% | 4.99M | $319.43M |
| 7 | Vanguard Portfolio Management LLC | 2.80% | 4.91M | $314.72M |
| 8 | Sumitomo Mitsui Trust Group, Inc. | 2.33% | 4.09M | $261.86M |
| 9 | Amova Asset Management Americas Inc | 2.33% | 4.09M | $261.86M |
| 10 | Goldman Sachs Group Inc | 2.14% | 3.76M | $240.90M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TEM
TEM Stock Slips Overnight: CEO-Linked $9.6M Share Sale Puts A Cloud Over 'AI As Physician' Story - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQcEdvYUtibjJtRTJzNG5aUDdaeFpfOC1LVFVIa183a2dVMThCUkpsc212V0JSUV9ZVjg4QVE3UzFpQUc1YUhGem5NUmlwX2QtVWc1cnowZ3VnMUlvSkV5TUdmempjMkdRQzlmY2NkdmgwMmFHTG5pLWRqRlhfNHRyQmZGNUJMeGU1NEIxZj…
Tempus AI (TEM) Stock Looks Fully Valued After Its 55% Jump - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxQWTZKb1VmcG5EMVkyZE9KZjlfTkJ4QWRZdlU4bnRabHNDdURPa0NZMHdCTk5LYkJoWGxkaFpreVVPU25tVmZpTXQ0cTMtS3JJMDR3em90RnZMR0g4akdCR1p0N1o5STVfLTc0Z21QTWMyd2dKS19ycGJqVk1yOGw5WUZHRW1Jb1BJckdOaz…
Tempus AI, Inc. $TEM Shares Acquired by Washington Trust Advisors Inc. - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPQ3pGcDR4dmhZMHBIQmtHZWEyNUhXdXlFQXlxUk1QaUF1a19ta1VobUR1MDdCbEdKWVFKdUZtblE5VXRxeXp4VDROSnVGMklaenR5Q05rV2cyRmlsXzM1MVRwQzJTSUsxZUtINk4tU0llWWEwRWlucnVxaWN5TTBMYXJvUWNURkxyZlJEMX…
Tempus AI Stock (TEM) Opinions on Analyst Upgrades and Personalized Medicine Momentum - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPUGM5cUYzaXhtQVFNTUNDaWEzWFJHaHk2b216U3lodEtnaFUta3Z0Y01FTk9wQnlLMmNwTjI3WUNwQjZmR21lSy1BeGdpSnZ2MFkyYThjckp6ZGxtLV9obUZRVlAyV016blJxQWlWY0ZLdWZtNFdobzBQSFAwSWxpOHhlTHF4cFpCYjVSZW…
Tempus AI (TEM) director’s stock sale follows preset plan - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOUlVCczhHVHZSZUxkMkNYMEdHNGNreWpyRzVYcld4VVQwVURibGNlTFRUQjJCbXVMTHI2REVlVjFGZE1VQmRwcGhPTmRLOTRTNWpSMWE2cDN3TTVMTWNLM2VJMFU3M1lETjBqOUlzX1ljTjh4eUd2ZTJMbnZMR1pETllZS0lVT0tfckI3cU…
Tempus AI stock upgraded at Piper Sandler (TEM:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxPZmVJclFFVzNHd2oyVHhZWXl4bThVeWJOTVlQc3I5d1FPWEc4MVplOElNMDdXV2ltSXdlejhCQ0hha0xnSEdtbS1sRjNQNU9adDRFbjZDOVZReXVXTjkxSFRuSk9TRkpNUi1CQlE3akh6RlJMdTd0Nkt2T1JoV3I3R1N3?oc=5" target=…
TEM — Frequently Asked Questions
What is the current share price of Tempus AI, Inc. (TEM)?
As of 2026-09-07 16:24 PDT, Tempus AI, Inc. (TEM) trades at $64.62 on NasdaqGS. Its 52-week range is $41.55 to $103.25.
What is the market capitalisation of TEM?
Tempus AI, Inc. (TEM) has a market capitalisation of $11.33B on NasdaqGS.
What is the P/E ratio of TEM?
TEM trades at a trailing price-to-earnings (P/E) ratio of -44.88. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 21.06.
What is the return on equity (ROE) of TEM?
TEM has a return on equity (ROE) of -67.44%. Its return on capital employed (ROCE) is -13.29%.
Is TEM a good stock to buy?
This page provides a data-driven analysis of Tempus AI, Inc. (TEM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.